Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...

Request To Download Free Sample of This Strategic Report @ The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global CAR T ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...

SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

CD19 and CD22 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase II for Unspecified B-Cell Lymphomas.

The 1-year event-free survival rate was 75.5%, and the 1-year overall survival rate was 93.5%. Bicistronic CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy can produce durable complete ...

CURE® selected some of the top stories from our coverage of the hematology conference. A phase 2 study explored a novel bicistronic CD19/CD22-directed CAR-T cell therapy for children with B-cell acute ...

The differential expression of surface markers allows for the identification of various B-cell stages, from pro-B cells to plasma cells. Surface antigens, such as CD19, CD20, CD22, BAFF-R, and CD40, ...

CARGO is currently evaluating firicabtagene autoleucel (firi-cel), an autologous CD22 chimeric antigen receptor ... relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.